Loading...
Clopidogrel, a thienopyridine derivative, inhibits platelet aggregation and, thereby, improves outcomes for patients undergoing percutaneous transluminal coronary angioplasty with stenting (Eur Heart J 2000; 21:2033). Because thrombosis plays such an important role in acute coronary syndrome (ACS), these investigators conducted the industry-sponsored, randomized, double-blind CURE trial: They compared clopidogrel (300-mg oral loading dose, then 75 mg daily) plus aspirin (dose range, 75 to 325 mg daily) with placebo plus aspirin in 12,562 ACS patients without ST-segment elevation (mean treatment duration, 9 months). All patients had been hospitalized with ACS within 24 hours of symptom onset at 482 centers in 28 countries over 22 months.
The …